Medpace Holdings, Inc. $MEDP Shares Acquired by Trexquant Investment LP

Key Points

• Trexquant Investment LP increased its stake in Medpace Holdings by 94.9%, holding approximately $21.08 million worth of shares after purchasing an additional 33,680 shares.
• Medpace reported a $3.10 EPS, surpassing analyst expectations, with a revenue increase of 14.2% year-over-year, bringing total revenue to $603.31 million for the quarter.
• Analysts have upgraded their price targets for Medpace, with some raising it to as high as $510, and the stock currently has a consensus rating of "Reduce" with a target price of $406.60.

Trexquant Investment LP lifted its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 94.9% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 69,181 shares of the company's stock after buying an additional 33,680 shares during the period. Trexquant Investment LP owned about 0.24% of Medpace worth $21,079,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the business. Whittier Trust Co. raised its stake in shares of Medpace by 47.3% during the 1st quarter. Whittier Trust Co. now owns 109 shares of the company's stock worth $33,000 after buying an additional 35 shares in the last quarter. Benjamin Edwards Inc. raised its stake in shares of Medpace by 3.1% during the 1st quarter. Benjamin Edwards Inc. now owns 1,201 shares of the company's stock worth $366,000 after buying an additional 36 shares in the last quarter. Assetmark Inc. raised its stake in shares of Medpace by 24.9% during the 1st quarter. Assetmark Inc. now owns 216 shares of the company's stock worth $66,000 after buying an additional 43 shares in the last quarter. Proficio Capital Partners LLC raised its stake in shares of Medpace by 6.4% during the 1st quarter. Proficio Capital Partners LLC now owns 777 shares of the company's stock worth $237,000 after buying an additional 47 shares in the last quarter. Finally, Park Avenue Securities LLC raised its stake in shares of Medpace by 1.8% during the 1st quarter. Park Avenue Securities LLC now owns 2,749 shares of the company's stock worth $838,000 after buying an additional 48 shares in the last quarter. 77.98% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other Medpace news, General Counsel Stephen P. Ewald sold 3,000 shares of the stock in a transaction on Monday, July 28th. The stock was sold at an average price of $450.00, for a total transaction of $1,350,000.00. Following the sale, the general counsel owned 10,343 shares in the company, valued at approximately $4,654,350. This represents a 22.48% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Susan E. Burwig sold 7,500 shares of the stock in a transaction on Monday, July 28th. The shares were sold at an average price of $450.14, for a total value of $3,376,050.00. Following the sale, the vice president owned 57,500 shares in the company, valued at approximately $25,883,050. This trade represents a 11.54% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 115,070 shares of company stock worth $52,085,751 in the last quarter. 20.30% of the stock is currently owned by corporate insiders.

Medpace Price Performance

NASDAQ:MEDP traded up $2.57 during trading hours on Friday, reaching $475.51. 408,536 shares of the company traded hands, compared to its average volume of 341,743. The firm's 50-day moving average is $395.75 and its 200-day moving average is $339.38. The stock has a market cap of $13.36 billion, a P/E ratio of 35.35, a P/E/G ratio of 2.99 and a beta of 1.42. Medpace Holdings, Inc. has a 1-year low of $250.05 and a 1-year high of $501.30.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its earnings results on Monday, July 21st. The company reported $3.10 EPS for the quarter, beating analysts' consensus estimates of $3.00 by $0.10. The firm had revenue of $603.31 million for the quarter, compared to analysts' expectations of $537.70 million. Medpace had a return on equity of 67.66% and a net margin of 18.74%.Medpace's quarterly revenue was up 14.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.75 EPS. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. As a group, research analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on MEDP. Barclays increased their target price on Medpace from $300.00 to $450.00 and gave the stock an "equal weight" rating in a research note on Wednesday, July 23rd. William Blair restated a "market perform" rating on shares of Medpace in a report on Wednesday, July 23rd. TD Cowen restated a "sell" rating and issued a $366.00 price target (up previously from $283.00) on shares of Medpace in a report on Wednesday, July 23rd. Mizuho upped their price target on Medpace from $328.00 to $510.00 and gave the stock an "outperform" rating in a report on Friday, July 25th. Finally, Cowen cut Medpace from a "buy" rating to a "sell" rating in a report on Wednesday, July 23rd. Two analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of "Reduce" and a consensus price target of $406.60.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.